Table 1.
Recipient # | Date of Marrow Graft | TBI Gy | Donor Marrow Cells × 108 / kg | Post-Marrow Grafting Immuno-suppression |
Date of Composite Tissue Allograft | % Donor Chimerism1 (weeks)2 | Post- Transplant Immuno-suppression |
Graft Rejection |
Weeks of follow-up3 |
|
---|---|---|---|---|---|---|---|---|---|---|
Before | After | |||||||||
G767 | 4/26/07 | 2 | 4.3 | MMF/CSP | 10/15/07 | G62.3 (0) L37.5 (0) |
G7.4 (35) L25.8 (35) |
No | No | >90 |
G244 | 5/16/03 | 1 | 9.2 | MMF/CSP | 10/29/07 | G62.5 (-1) L49.4 (-1) |
G100 (31) L100 (31) |
No | No | >77 |
G500 | 12/22/04 | 2 | 4.8 | MMF/Rapa | 12/18/07 | G50.0 (-3) L66.0 (-3) |
G36.1 (26) L42.4 (26) |
No | No | >52 |
G969 | 12/13/07 | 2 | 4.1 | MMF/CSP | 4/14/08 | G94.6 (-4) L49.5 (-4) |
G100 (53) L100 (53) |
No | No | >52 |
G949 | 1/4/08 | 1 | 2.8 | MMF/CSP | 10/27/08 | G69.5 (0) L48.4 (0) |
G38.3 (52) L45.3 (52) |
No | No | >52 |
Data are presented as percent donor granulocytes (G) and lymphocytes (L).
Chimerism analyzed in weeks before or after composite tissue graft, week = 0.
Weeks of follow-up after composite tissue graft, week = 0.
G767 and G969 received 2 Gy TBI (day = 0) with postgrafting immunosuppression of MMF (10 mg/kg B.I.D. subq., days 0-27) and CSP (15 mg/kg B.I.D. orally , days -1-35) and received HCT on a protocol specifically for this study.
The following dogs received HCT under separate studies and were later transferred to the present study as mixed chimeras. G244 received 1 Gy TBI with postgrafting immunosuppression of MMF (10 mg/kg B.I.D subq., days 0-27) CSP (15 mg/kg B.I.D. orally, days -1-35) and methotrexate (0.4 mg/kg, I.V. days 1, 3, 6, 11).
G500 received 2 Gy TBI with postgrafting immunosuppression of MMF (10 mg/kg B.I.D subq., days 0-34) and sirolimus (0.05 mg/kg, daily, subq, day -5 to 25).
G949 received 1 Gy TBI on day = 0, recombinant canine CTLA4-Ig (4.0 mg/kg I.V. days -7 and -5) donor PBMC (1 × 106 cells/kg on days -7 and -5 injected subq and I.V.) and post grafting immunosuppression consisting of MMF (10 mg/kg B.I.D. subq., days 0-27) and CSP (15 mg/kg B.I.D. orally , days -1-35).